

Domino [Pd]-Catalysis: One-Pot Synthesis of Isobenzofuran-1(3*H*)-ones

Lodi Mahendar and Gedu Satyanarayana*

Department of Chemistry, Indian Institute of Technology Hyderabad, Kandi-502 285, Sangareddy, Medak District, Telangana, India

Supporting Information

R¹ (CH₂O)_n
Pd(OAc)₂/Xanth-Phos
base, o-xylene,
$$\Delta$$

R¹ (CH₂O)_n
Pd(OAc)₂/Xanth-Phos
base, o-xylene, Δ

R¹ (III)
R² (R³)
R³ (CH₂O)_n
R³ (CH₂O)_n
R⁴ (amenable to 1° or 2° or 3° alcohols
non-toxic (CH₂O)_n served as CO source
synthesis of isobenzofuran1-(3H) ones
application to the synthesis of drugs

R¹ = OMe, OBn, F

R² (R³)
R³ = H, alkyl, aryl, heteroaryl

ABSTRACT: An efficient domino [Pd]-catalysis for the synthesis of isobenzofuran-1(3H)-ones is presented. The strategy shows broad substrate scope and is amenable to o-bromobenzyl tertiary/secondary/primary alcohols. Significantly, the method was applied to the synthesis of antiplatelet drug n-butyl phthalide and cytotoxic agonist 3a-[4'-methoxylbenzyl]-5,7-dimethoxyphthalide.

■ INTRODUCTION

Isobenzofuranones (phthalides) are an emerging class of compounds in medicinal chemistry. Phthalides are found in many naturally occurring compounds that exhibit interesting biological activities (Figure 1). They are proven to be useful in




Figure 1. Biologically active natural isobenzofuranones.

the treatment of circulatory and heart diseases. ^{1a} Phthalides also act as key structural units in organic synthesis, particularly in the synthesis of functionalized anthracenes, naphthalenes, and naphthacene-based natural products. ² As a result, their synthesis has attracted much attention from organic as well as pharmaceutical chemists. ³ In this context, reasonable attempts have been made on the synthesis of isobenzofuran-1(3H)-ones. ⁴ Nevertheless, some of the reported methods still lack simplicity and generality. ⁵

Domino processes are extremely useful in organic synthesis, as they can be performed under simple one-step conditions, thus eliminating tedious isolation and purification of intermediate products(s). Therefore, such processes are ultimately useful in saving energy and minimizing the waste formation. Transition metal catalysis has been proven to be an efficient tool for the development of new synthetic methods, especially in the creation of new C–C and C–X heteroatom bonds with increasing molecular complexity. In continuation of our ongoing research interests in domino processes using transition metal-catalysis, we have reported an efficient [Cu]-catalyzed domino one-pot method for the synthesis of isobenzofuran-1(3H)-ones using nontoxic K₄[Fe(CN)₆] as the source of CO, under environmentally benign conditions (Scheme 1). However, this process was limited to obromobenzyl tertiary alcohols. Though carbon monoxide (CO)⁹ is an inexpensive and readily available carbonylation

Scheme 1. Present Study and Our Previous Approach for the Synthesis of Isobenzofuranones

Our previous work (ref. 4i):

$$R^{2} R^{3}$$

$$R^{1} R^{1} R^{2} R^{3}$$

$$R^{1} R^{2} R^{3}$$

$$R^{3} R^{4} R^{2} R^{3}$$

$$R^{2} R^{3} R^{3}$$

$$R^{2} R^{3}$$

$$R^{3} R^{2} R^{3}$$

$$R^{4} R^{2} R^{3}$$

$$R^{4} R^{2} R^{3}$$

$$R^{4} R^{2} R^{3}$$

$$R^{5} R^{2} R^{3}$$

$$R^{5} R^{2} R^{3}$$

$$R^{5} R^{2} R^{3}$$

$$R^{5} R^{5} R^{5}$$

$$R^{5} R^{5}$$

$$R^{5} R^{5} R^{5}$$

$$R^{5} R^{5}$$

Received: June 9, 2016
Published: August 10, 2016

The Journal of Organic Chemistry

source, its toxicity and the requirement of high pressure operations limits its synthetic applications. CO remains significant to the advancement of carbonylation reactions. 10 On these grounds, Skrydstrup et al. reported CO-free carbonylations using in situ-generated carbon monoxide.¹¹ Also, the research group of Beller et al. developed new methods using CO surrogates, such as aryl formates and $[Mo(CO)_6]^{12}$ However, compared to all CO surrogates used in previous reports, paraformaldehyde was found superior, because it is inexpensive, stable, and easily used. As a result, the research group of Beller disclosed an elegant approach demonstrating the palladium-catalyzed reductive carbonylations and alkoxycarbonylations using paraformaldehyde as an external CO source. 13a Subsequently, Xiao-Feng Wu et al. disclosed paraformaldehyde-mediated carbonylations for the synthesis of benzoxazinones. 13b Paraformaldehyde had also been used in Rh-catalyzed CO-free carbonylations of alkynes. 14 However, paraformaldehyde has not been properly explored for [Pd]catalyzed carbonylation. 13,15 In continuation of our research interests on domino transition metal catalysis, herein we report an efficient [Pd]-catalyzed concise approach for the syntheses of phthalides, using paraformaldehyde as the source of CO (Scheme 1). Significantly, the strategy was extended to the synthesis of isobenzofuranone-based natural products, from simple o-bromobenzyl alcohols. Remarkably, unlike our previous report,4i the present strategy was proved to be very versatile, as it was amenable to primary/secondary/tertiary obromobenzyl alcohols and was also applied to the synthesis of natural/drug products. To the best of our knowledge, there are no reports on the synthesis of isobenzofuran-1(3H)-ones using paraformaldehyde as carbonylating agent.

■ RESULT AND DISCUSSION

To initiate the synthetic study, we have chosen *o*-bromobenzyl tertiary alcohol **1aa** as a model. Thus, the reaction was carried out with paraformaldehyde as CO source in the presence of Pd(OAc)₂ and base KOAc in H₂O, and with PPh₃ and Xanth-Phos, respectively. The desired product **2aa** was formed, albeit in poor to moderate yields (Table 1, entries 1 and 2). The reaction was then conducted under different solvents using Xanth-Phos as the ligand (Table 1, entries 3 to 10). Gratifyingly, *o*-xylene was found as the best solvent and afforded product **2aa** in excellent yield (Table 1, entry 6). Other conditions used, such as different bases in *o*-xylene, were found inferior to the conditions of entry 6 (Table 1, entries 11–18).

With the optimized conditions in hand (Table 1, entry 6), to check the scope and generality of the method, the reaction was explored with other o-bromobenzyl tertiary alcohols 1aa-1bd. To our delight, the reaction showed broad substrate scope and furnished the benzofuranones 2aa-2bd, in very good to excellent yields (Table 2). Interestingly, the reaction was successful with dialkyl substituents (entries 2aa-2ar), cyclic tertiary alcohol 1as (entry 2as), alkyl-aryl groups (entries 2at-2az), alkyl-heteroaryl groups (entries 2ba and 2ab) as well as diaryl substituents (entries 2bc and 2bd). Remarkably, the reaction showed broad functional group tolerance, such as donating groups on the o-bromoarene moiety (compare entries 2ae vs 2ar).

After successful synthesis of benzofuranones 2aa-2bd (Table 2) with a quaternary carbon atom, to demonstrate the scope and generality of the method, we planned to explore the reaction with o-bromobenzyl secondary alcohols. Thus, the

Table 1. Screening Conditions for the Synthesis of 2aa

1aa

$$\begin{array}{c} \text{Me} \quad \text{Me} \quad \text{Me} \quad \\ \text{OH} \quad \\ \text{Br} \quad \\ \text{DH} \quad \\ \\ \text{Br} \quad \\ \\ \text{DH} \quad \\ \\ \text$$

laa		Zaa			
	entry ^a	ligand (10 mol %)	solvent	base (2 equiv)	2aa (%) ^b
	3	PPh_3	H_2O	KOAc	36 ^d
	2	Xant-Phos	H_2O	KOAc	51 ^d
	3	Xant-Phos	DMA	KOAc	_c
	4	Xant-Phos	DMSO	KOAc	45 ^d
	5	Xant-Phos	DMF	KOAc	41 ^d
	6	Xant-Phos	o-xylene	KOAc	93
	7	Xant-Phos	dioxane	KOAc	42 ^d
	8	Xant-Phos	CH ₃ CN	KOAc	60
	9	Xant-Phos	p-xylene	KOAc	87
	10	Xant-Phos	DCE	KOAc	_c
	11	Xant-Phos	o-xylene	K_3PO_4	71
	12	Xant-Phos	o-xylene	K_2CO_3	61
	13	Xant-Phos	o-xylene	Na_2CO_3	_c
	14	Xant-Phos	o-xylene	NaOAc	66
	15	Xant-Phos	o-xylene	Cs_2CO_3	48 ^d
	16	Xant-Phos	o-xylene	NEt ₃	46 ^d
	17	Xant-Phos	o-xylene	$HNEt_2$	48 ^d
	18	Xant-Phos	o-xylene	DMED	26 ^d

^aAll reactions were carried out on a 0.5 mol scale of 1aa and 2.5 mol scale of $(CH_2O)_n$ and with solvent (0.5 mL). ^bIsolated yields of chromatographically pure products. ^cStarting material was recovered. ^dStarting material 1aa was recovered along with the product 2aa.

reaction was performed with o-bromobenzyl secondary alcohols 1be-1bo, under standard conditions. Gratifyingly, the reaction was quite successful and furnished the desired lactones 2be-2bo, in fair to good yields (Table 3). Notably, the reaction proceeded smoothly with different alkyl substituents on the carbinol center (Table 3, entries 2be-2bo). Significantly, this strategy was successfully applied to the synthesis of an antiplatelet drug n-butylphthalide (NBP)¹⁶ **2bm**. Notably, the reaction was also amenable with cyclic alkyl as well as benzyl groups (entries 2bn and 2bo). Most significantly, demonstrating the utility of the current method over previous reported methods, primary alcohols 1bp-1bs were successfully cyclized to give the desired lactones 2bp-2bs (Table 3). It is worth noting that the reaction with primary alcohols 1bp-1bs was not successful with the base KOAc. However, to our delight, changing the base from KOAc to Na2CO3 gave the desired lactones in good yields (Table 3). In contrast to our previous report, 4i which was limited to o-bromobenzyl tertiary alcohols, the present protocol is amenable to o-bromobenzyl secondary/ primary alcohols.

To demonstrate the utility of the domino [Pd]-catalysis process, we applied the strategy to the synthesis of a cytotoxic antagonist, 3a-[4'-methoxybenzyl]5,7-dimethoxypthalide $2bt^{17}$ (Scheme 2). Therefore, the required secondary alcohol 1bt was synthesized using established conditions as depicted in Scheme 2. Thus, NBS-promoted bromination and methylmagnesium iodide addition, followed by oxidation protocol, afforded the acetophenone 4 (Scheme 2). The [Pd]-catalyzed α -arylation of acetophenone 4 and reduction of the resultant ketone 3 with NaBH₄ furnished the alcohol 1bt (Scheme 2). Finally, the key [Pd]-catalyzed lactonization of 1bt was amenable and furnished

The Journal of Organic Chemistry

Table 2. Syntheses of Isobenzofuranones 2aa-2bd from o-Bromobenzyl Tertiary Alcohols 1aa-1bd^{a,b}

"Reaction conditions: 1aa-1bd (0.50 mmol), (CH₂O)_n (2.5 mmol), Pd(OAc)₂ (5 mol %), Xanth-Phos (10 mol %), KOAc (2 equiv) in 0.5 mL o-xylene, at 140 °C for 24 h. ^bIsolated yields of chromatographically pure products.

the cytotoxic agonist 3a-[4'-methoxybenzyl]-5,7-dimethoxyphthalide 2bt in its racemic form, in good yield (Scheme 2).

Interestingly, when we attempted the reaction of silyl ether 9, the benzofuranone 2ai was obtained in 67% yield (Scheme 3). This is probably due to in situ deprotection of the TMS group, which might be feasible under basic reaction conditions and then the usual [Pd]-catalyzed lactonization process.

Further, the chemical structure of 2 was confirmed by single crystal X-ray diffraction analysis of 2bq and 2br as shown in Figure 2 (see; Supporting Information for X-ray data of 2bq and 2br).

On the basis of established reports using paraformaldehyde as CO-free carbonylating agent and experimental studies probing the mechanistic path, ¹³ the plausible reaction mechanism for the formation of isobenzofuranones 2 is shown in Scheme 4. Thus, the initial oxidative insertion of Pd⁰- catalyst into the C–Br bond of 1 generates the aryl-Pd^{II} species A. Then the migratory insertion of CO on A furnishes new Pd^{II}-species B. Subsequent intramolecular nucleophilic chelation of the OH group and concomitant elimination of HBr leads to the six-membered Pd^{II}-intermediate C. Finally, reductive elimination of C through the formation of Pd⁰-catalyst gives isobenzofuranones 2 and thus completes the catalytic cycle. Presumably, CO might be formed via an

independent path by the reaction of paraformdaldehyde with the $\lceil Pd \rceil$ -catalyst.

CONCLUSIONS

We have described an efficient domino [Pd]-catalysis for the one-pot synthesis of isobenzofuran-1(3H)-ones. Unlike our previous report, the present strategy showed broad substrate scope and is amenable to *o*-bromobenzyl tertiary/secondary/primary alcohols. Significantly, the method was also successfully applied to the synthesis of antiplatelet drug *n*-butyl phthalide and cytotoxic agonist 3a-[4'-methoxylbenzyl]-5,7-dimethoxyphthalide.

■ EXPERIMENTAL SECTION

General Considerations. IR spectra were recorded on a FTIR spectrophotometer. ^1H NMR spectra were recorded on 400 MHz spectrometer at 295 K in CDCl₃; chemical shifts (δ ppm) and coupling constants (Hz) are reported in standard fashion with reference to either internal standard tetramethylsilane (TMS) (δ_H = 0.00 ppm) or CHCl₃ (δ_H = 7.25 ppm). ^{13}C NMR spectra were recorded on 100 MHz spectrometer at RT in CDCl₃; chemical shifts (δ ppm) are reported relative to CHCl₃ [δ_C = 77.00 ppm (central line of triplet)]. In the ^{13}C NMR spectra, the nature of carbons (C, CH, CH₂, and CH₃) was determined by recording the DEPT-135 spectra and is given in parentheses and noted as s = singlet (for C), d =

The Journal of Organic Chemistry

Table 3. Syntheses of Isobenzofuranones 2be-2bs from $1be-1bs^a-d$

^aReaction conditions: 1be-1bo/1bp-1bs (0.50 mmol), (CH₂O)_n (2.5 mmol), Pd(OAc)₂ (5 mol %), Xanth-Phos (10 mol %), base (2 equiv) in 0.5 mL o-xylene, at 140 °C for 24 h. ^bFor 1be-1bo, KOAc was used as the base. In the case of 1bp-1bs, Na2CO3 was used as the base. ^dIsolated yields of chromatographically pure products.

Scheme 2. Synthesis of Cytotoxic Agonist 3a-[4'-Methoxybenzyl]-5,7-dimethoxyphthalide 2bt

doublet (for CH), t = triplet (for CH₂), and q = quartet (for CH₃). In the ¹H NMR spectra, the following abbreviations were used throughout: s = singlet, d = doublet, t = triplet, q = quartet, qui = quintet, m = multiplet, and br s = broad singlet. The assignment of signals was confirmed by ¹H, ¹³C CPD (carbon proton decoupled), and DEPT spectra. High-resolution mass spectra (HR-MS) were

Scheme 3. Formation of Isobenzofuranone 2ai from TMS Ether 9




Figure 2. X-ray crystal structures for products 2bq and 2br.

Scheme 4. Plausible Reaction Path for the Formation of 2

recorded using Q-TOF multimode source. Melting points were determined on an electrothermal melting point apparatus and are uncorrected. Benzaldehydes, immidazole, aryl halides, methyl iodide, bromoethane, Mg metal, and Na₂SO₄ were commercially available (local made) used without further purification, Pd(OAc)2, PPh3, Xanth-Phos, (HCHO),, Cs₂CO₃, KOAc, K₃PO₄, K₂CO₃, Na₂CO₃, NaOAc, NEt3, NHEt2, and DMED (dimethylethelenediamine) purchased from a commercial source. Dry solvents were used: diethyl ether, toluene, dioxane, and THF were dried over sodium metal, and DCM, DMA, CH3CN, DCE, and DMF were dried over calcium hydride.

All the solvents (diethyl ether, THF, DCM, DMF, p-xylene, DMSO, and o-xylene) are commercially available (LR grade). All small-scale dry reactions were carried out using the standard syringe-septum technique. Reactions were monitored by TLC on silica gel using a combination of petroleum ether and ethyl acetate as eluents. Solvents were distilled prior to use; petroleum ether with a boiling range of 40 to 60 °C was used. Acme silica gel (60–120 mesh) was used for column chromatography (approximately 20 g per 1 g of crude material).

General Procedure (for the synthesis of lactones) (2aa-2bt). To an oven-dried Schlenk tube were added 2-bromobenzyl alcohols 1 (0.50 mmol), paraformaldehyde (2.50 mmol), Pd(OAc)₂ (0.02 mmol), Xanth-Phos (0.05 mmol), base [(1.00 mmol) for primary alcohols Na₂CO₃ for tertiary and secondary alcohols KOAc], and solvent (o-xylene) (0.5 mL). The resulting reaction mixture was stirred at 140 °C for 24 h. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mixture was allowed to cool to room temperature and then diluted with (10 mL) ethyl acetate, and saturated NH₄Cl was added followed by extraction with ethyl acetate. The organic layers were dried (Na₂SO₄) and concentrated in vacuo. Purification of the residue by silica gel column chromatography using petroleum ether/ethyl acetate as the eluent furnished the lactone 2.

1-(2-Bromo-3,5-dimethoxyphenyl)ethanol (1bu). To a cold (0 °C), magnetically stirred solution of a bromobenzaldehyde 7f (1.29 mmol) in dry dry ether (2 mL) was added methylmagnesium iodide (2.59 mmol) [prepared from magnesium (2.59 mmol) and methyl iodide (2.59 mmol) in 10 mL of dry ether]. The reaction mixture was stirred at 0 °C to room temperature for 3 h. It was then poured into saturated aqueous NH₄Cl solution and extracted with ethyl acetate (3 × 15 mL). The combined organic layers were dried (Na₂SO₄) and concentrated in vacuo. The crude secondary alcohol 1bu was purified by column chromatography on silica using petroleum ether/ethyl acetate (85:15) as eluent and isolated as a white colored solid 89% yield (339 mg): mp 76-78 °C; [TLC (petroleum ether/ethyl acetate 8:2, $R_f(7f) = 0.40$, $R_f(1bu) = 0.30$, UV detection]. ¹H NMR (CDCl₃) 400 MHz): δ = 6.79 (d, J = 2.9 Hz, 1H), 6.40 (d, J = 2.4 Hz, 1H), 5.27 (q, J = 6.3 Hz, 1H), 3.86 (s, 3H), 3.82 (s, 3H), 2.00 (br s, 1H), 1.45(d, J = 6.3 Hz, 3H) ppm. ¹³C NMR (CDCl₃, 100 MHz): $\delta = 160.1$ (C_q) , 156.4 (C_q) , 146.8 (C_q) , 102.4 (CH), 101.8 (C_q) , 98.8 (C_q) , 69.4 (CH), 56.3 (CH_3) , 55.6 (CH_3) , 23.4 (CH_3) ppm. IR (MIR-ATR, $4000-600 \text{ cm}^{-1}$): $\nu_{\text{max}} = 3320$, 2932, 1490, 1345, 1286, 1181, 1050, 962, 758, 689 cm $^{-1}$. HR-MS (ESI+) m/z calculated for $[C_{10}H_{14}BrO_3]^{-1}$ $= [M + H]^+$: 261.0121; found: 261.0125.

1-(2-Bromophenyl)butan-1-ol (1bj). To a cold (0 °C), magnetically stirred solution of a bromobenzaldehyde 7a (2.70 mmol) in dry THF (2 mL) were added propylmagnesium bromide (5.40 mmol) [prepared from magnesium (5.40 mmol), 1-bromopropane (5.40 mmol), and a catalytic amount of iodine in 10 mL of dry THF]. The reaction mixture was stirred at 0 °C to room temperature for 3 h. It was then poured into saturated aqueous NH₄Cl solution and extracted with ethyl acetate (3 × 15 mL). The combined organic layers were dried (Na₂SO₄) and concentrated in vacuo. The crude secondary alcohol 1bj was purified by column chromatography on silica using petroleum ether/ethyl acetate (92:08) as eluent and isolated as a colorless liquid 78% yield (486 mg); [TLC (petroleum ether/ethyl acetate 9:1, $R_f(7a) = 0.50$, $R_f(1bj) = 0.40$, UV detection]. ¹H NMR (CDCl₃ 400 MHz): $\delta = 7.58-7.40$ (m, 2H), 7.31 (dd, J = 7.3 and 7.3 Hz, 1H), 7.10 (dd, J = 7.8 and 7.3 Hz, 1H), 5.10–5.00 (m, 1H), 2.23 (br s, 1H), 1.80-1.60 (m, 2H), 1.58-1.35 (m, 2H), 0.95 (t, J = 7.3 Hz, 3H) ppm. 13 C NMR (CDCl₃, 100 MHz): δ = 143.9 (C_q), 132.5 (CH), 128.6 (CH), 127.6 (CH), 127.3 (CH), 121.9 (C_q), 72.6 (CH), 39.8 (CH₂), 18.9 (CH₂), 13.8 (CH₃) ppm. IR (MIR-ATR, 4000-600 cm⁻¹): $\nu_{\text{max}} = 3320, 2930, 1496, 1341, 1286, 1181, 1050, 962, 750, 687$ cm⁻¹. HR-MS (ESI+) m/z calculated for $[C_{10}H_{13}OBrNa]^+ = [M +$ Na]+: 251.0042; found: 251.0046.

1-(2-Bromo-3,4,5-trimethoxyphenyl)butan-1-ol (1bl). To a cold (0 °C), magnetically stirred solution of a bromobenzaldehyde 7d (2.0 mmol) in dry THF (2 mL) were added propylmagnesium bromide (4.0 mmol) [prepared from magnesium (4.0 mmol), 1-bromopropane (4.0 mmol), and a catalytic amount of iodine in 10 mL of dry THF]. The reaction mixture was stirred at 0 °C to room temperature for 3 h.

It was then poured into saturated aqueous NH₄Cl solution and extracted with ethyl acetate (3×15 mL). The combined organic layers were dried (Na₂SO₄) and concentrated in vacuo. The crude secondary alcohol 1bl was purified by column chromatography on silica using petroleum ether/ethyl acetate (75:25) as eluent and isolated as a brown colored viscous liquid 85% yield (549 mg); [TLC (petroleum ether/ethyl acetate 7:3, $R_f(7\mathbf{d}) = 0.60$, $R_f(1\mathbf{bl}) = 0.50$, UV detection]. ¹H NMR (CDCl₃ 400 MHz): $\delta = 6.91$ (s, 1H), 5.08-5.00 (m, 1H), 3.84 (s, 3H), 3.83 (s, $2 \times 3H$), 2.28 (br s, 1H), 1.80-1.30 (m, 4H), 0.93 (t, J = 7.3 Hz, 3H) ppm. ¹³C NMR (CDCl₃, 100 MHz): $\delta = 152.9$ (C_q) , 150.2 (C_q) , 141.9 (C_q) , 139.8 (C_q) , 107.9 (C_q) , 105.7 (CH), 72.5 (CH), 61.0 (CH₃), 60.9 (CH₃), 56.0 (CH₃), 39.8 (CH₂), 19.0 (CH₂), 13.8 (CH₃) ppm. IR (MIR-ATR, 4000–600 cm⁻¹): $\nu_{\text{max}} =$ 3349, 2930, 1493, 1355, 1276, 1181, 1052, 962, 759, 679 cm⁻¹. HR-MS (ESI+) m/z calculated for $[C_{13}H_{19}O_4BrNa]^+ = [M + Na]^+$: 341.0359; found: 341.0350.

1-(2-Bromo-3,5-dimethoxyphenyl)ethanone (4). To a magnetically stirred solution of the secondary alcohol **1bu** (1.21 mmol) in dry CH₂Cl₂ (10 mL) was added a homogeneous mixture (1:1) of PCC (3.64 mmol) and silica gel. The resulting reaction mixture was stirred at room temperature for 2 h. Filtration of the reaction mixture through a short silica column with excess CH₂Cl₂ furnished the pure ketone 4 that was isolated as a pale yellow colored oil 94% yield (281 mg); [TLC (petroleum ether/ethyl acetate 8:2, R_f (**1bu**) = 0.40, R_f (4) = 0.50, UV detection]. ¹H NMR (CDCl₃ 400 MHz): δ = 6.51 (d, J = 2.9 Hz, 1H), 6.46 (d, J = 2.4 Hz, 1H), 3.87 (s, 3H), 3.79 (s, 3H), 2.59 (s, 3H) ppm. ¹³C NMR (CDCl₃, 100 MHz): δ = 202.4 (C_q), 160.0 (C_q), 156.9 (C_q), 144.3 (C_q), 103.8 (CH), 101.1 (CH), 98.9 (C_q), 56.5 (CH₃), S5.7 (CH₃), 30.6 (CH₃) ppm. IR (MIR-ATR, 4000–600 cm⁻¹): ν_{max} = 2939, 1689, 1546, 1460, 1355, 1280, 1171, 1055, 962, 758, 680 cm⁻¹. HR-MS (ESI+) m/z calculated for [C₁₀H₁₁BrO₃Na]⁺ = [M + Na]⁺: 280.9784; found: 280.9789.

1-(2-Bromo-3,5-dimethoxyphenyl)-2-(4-methoxyphenyl)ethanone (3). In an oven-dried Schlenk tube under nitrogen atmosphere were added *p*-iodoanisole 5 (1.34 mmol), *o*-bromoacetophenone 4 (1.22 mmol), Pd(OAc)₂ (2 mol %), xantphos (4 mol %), and 'BuOK (2.44 mmol) followed by addition of dry toluene (4 mL). The resulting reaction mixture was stirred at 80 °C for 20 min. Progress of the reaction was monitored by TLC until the reaction was completed. The reaction mixture was then quenched with saturated aqueous NH₄Cl, and the aqueous layer was extracted with ethyl acetate (3 × 20 mL). The combined organic layers were dried (Na₂SO₄) and concentrated in vacuo. The crude ketone 3 was purified by column chromatography on silica using petroleum ether/ethyl acetate (85:15) as eluent and isolated as a pale yellow colored liquid 66% yield (296 mg); [TLC (petroleum ether/ethyl acetate 8:2, $R_f(4)$ = 0.60, $R_{\rm f}(3)$ = 0.50, UV detection]. ¹H NMR (CDCl₃ 400 MHz): δ = 7.15 (d, J = 8.8 Hz, 2H), 6.84 (d, J = 8.8 Hz, 2H), 6.49 (d, J = 2.9 Hz, 1H), 6.27 (d, J = 2.9 Hz, 1H), 4.13 (s, 2H), 3.87 (s, 3H), 3.78 (s, 3H), 3.73 (s, 3H) ppm. 13 C NMR (CDCl₃, 100 MHz): $\delta = 202.7$ (C_q), 159.9 (C_a), 158.7 (C_a), 156.7 (C_a), 144.0 (C_a), 130.8 (CH), 125.4 (C_0) , 114.0 (CH), 103.9 (CH), 100.8 (CH), 98.6 (C_0), 56.4 (CH₃), 55.7 (CH₃), 55.2 (CH₃), 48.8 (CH₂) ppm. IR (MIR-ATR, 4000–600 cm⁻¹): $\nu_{\text{max}} = 2938$, 1679, 1550, 1453, 1340, 1280, 1176, 1050, 962, 756, 680 cm⁻¹. HR-MS (ESI+) m/z calculated for $[C_{17}H_{18}BrO_4]^+ =$ $[M + H]^+$: 365.0383; found: 365.0378.

1-(2-Bromo-3,5-dimethoxyphenyl)-2-(4-methoxyphenyl)ethanol (1bt). To a magnetically stirred solution of the aryl ketone 3 (0.54 mmol) in dry MeOH (10 mL) was added NaBH₄ (1.08 mmol). The resulting reaction mixture was stirred at room temperature for 2 h. It was then poured into saturated aqueous NH₄Cl solution and extracted with ethyl acetate (3 × 15 mL). The combined organic layers were dried (Na₂SO₄) and concentrated in vacuo. The crude secondary alcohol 1 was purified by column chromatography on silica using petroleum ether/ethyl acetate (85:15) as eluent and isolated as a colorless oil 92% yield (186 mg); [TLC (petroleum ether/ethyl acetate 8:2, $R_f(3) = 0.50$, $R_f(1bt) = 0.30$, UV detection]. ¹H NMR (CDCl₃ 400 MHz): δ = 7.24 (d, J = 8.8 Hz, 2H), 6.87 (d, J = 8.8 Hz, 2H), 6.79 (d, J = 2.9 Hz, 1H), 6.43 (d, J = 2.9 Hz, 1H), 5.28–5.20 (m, 1H), 3.88 (s, 3H), 3.81 (s, 3H), 3.80 (s, 3H), 3.20–3.10 (m, 1H),

2.65–2.55 (m, 1H), 2.11 (br s, 1H) ppm. 13 C NMR (CDCl₃, 100 MHz): $\delta=160.0$ (Cq), 158.4 (Cq), 158.3 (Cq), 145.0 (Cq), 130.4 (CH), 130.3 (Cq), 113.9 (CH), 102.8 (CH), 101.9 (Cq) 98.9 (Cq), 74.3 (CH), 56.3 (CH₃), 55.5 (CH₃), 55.2 (CH₃), 43.1 (CH₂) ppm. IR (MIR-ATR, 4000–600 cm $^{-1}$): $\nu_{\rm max}=3329$, 2930, 1530, 1443, 1350, 1240, 1178, 1050, 945, 750, 676 cm $^{-1}$. HR-MS (ESI+) m/z calculated for [C₁₇H₁₉BrO₄Na] $^+$ = [M + Na] $^+$: 389.0359; found: 389.0364.

[(2-(2-Bromo-5-methoxyphenyl)butan-2-yl)oxy]trimethylsilane (9). To a magnetically stirred solution of the tertiary alcohol 1ai (0.39 mmol) and imidazole (3 mmol) in dry CH2Cl2 (6 mL) was added trimethylsilyl chloride (3 mmol) at 0 °C. The resulting reaction mixture was stirred at room temperature for 4 h. The reaction mixture was quenched and extracted with CH_2Cl_2 (3 × 15 mL). The collected organic layers were dried (Na₂SO₄) and concentrated under reduced pressure. Purification of the residue on a silica gel column chromatography (petroleum ether/ethyl acetate 97:03) as eluent furnished trimethylsilyl ether 9 in 89% yield (114 mg) as colorless viscous liquid: [TLC (petroleum ether/ethyl acetate 9:1, $R_f(1ai)$ = 0.40, $R_f(9) = 0.60$, UV detection]. ¹H NMR (CDCl₃ 400 MHz) $\delta =$ 7.42 (d, 1H, J = 8.3 Hz), 7.33 (d, 1H, J = 3.4 Hz), 6.61 (dd, 1H, J = 8.3and 3.4 Hz), 3.78 (s, 3H), 2.55-2.40 (m, 1H), 1.85-1.71 (m, 1H), 1.76 (s, 3H), 0.64 (t, 3H, J = 7.3 Hz), 0.18 (s, 9H) ppm; ¹³C NMR (CDCl₃, 100 MHz) $\delta = 158.5$ (C_q), 147.1 (C_q), 135.5 (CH), 115.5 (CH), 113.1 (CH), 110.1 (C_q), 79.4 (C_q), 55.2 (CH₃), 33.5 (CH₂), 28.0 (CH₃), 8.5 (CH₃), 2.4 (3 × CH₃) ppm; IR (MIR-ATR, 4000– 600 cm⁻¹) $\nu_{\text{max}} = 2958$, 1568, 1460, 1372, 1249, 1170, 1056, 835, 752, 673 cm⁻¹; HR-MS (ESI+) m/z calculated for $[C_{14}H_{23}^{81}BrNaSiO_2]^+$ = $[M + Na]^+$ 353.0543, found 353.0540.

3-Ethyl-5-methoxyisobenzofuran-1(3H)-one (2bg). This compound was prepared according to the GP using petroleum ether/ethyl acetate (85:15) as eluent and isolated as a brown colored viscous liquid 72% yield (75 mg): [TLC (petroleum ether/ethyl acetate 8:2, $R_f(1bg) = 0.50$, $R_f(2bg) = 0.40$, UV detection]. ¹H NMR (CDCl₃ 400 MHz): δ = 7.76 (d, J = 8.3 Hz, 1H), 6.99 (dd, J = 1.9 and 8.3 Hz, 1H), 6.93 (d, J = 1.9 Hz, 1H), 5.33 (dd, J = 4.4 and 7.3 Hz, 1H), 3.87 (s, 3H), 2.00–2.15 (m, 1H), 1.85–1.70 (m, 1H), 0.96 (t, J = 7.3 Hz, 3H) ppm. ¹³C NMR (CDCl₃, 100 MHz): δ = 170.4 (C_q), 164.6 (C_q), 152.4 (C_q), 127.1 (CH), 118.5 (C_q), 116.2 (CH), 105.8 (CH), 81.5 (C_q), 55.8 (CH₃), 27.6 (CH₂), 8.7 (CH₃) ppm. IR (MIR-ATR, 4000–600 cm⁻¹): $\nu_{\text{max}} = 2947$, 1750, 1598, 1465, 1338, 1282, 1190, 1054, 965, 741, 692 cm⁻¹. HR-MS (ESI+) m/z calculated for [C₁₁H₁₃O₃]⁺ = [M + H]⁺: 193.0859; found: 193.0853.

3-Isopropyl-5-methoxyisobenzofuran-1(3H)-one (2bi). This compound was prepared according to the GP using petroleum ether/ethyl acetate (85:15) as eluent and isolated as a colorless oil 66% yield (68 mg): [TLC (petroleum ether/ethyl acetate 8:2, $R_{\rm f}({\bf 1bi}) = 0.50$, $R_{\rm f}({\bf 2bi}) = 0.40$, UV detection]. ¹H NMR (CDCl₃ 400 MHz): δ = 7.88 (d, J = 7.8 Hz, 1H), 7.65 (dd, J = 1.5 and 7.8 Hz, 1H), 7.51 (dd, J = 7.3 and 7.3 Hz, 1H), 7.43 (d, J = 7.8 Hz, 1H), 5.36 (d, J = 3.9 Hz, 1H), 2.35–2.20 (m, 1H), 1.11 (d, J = 7.3 Hz, 3H), 0.79 (d, J = 6.8 Hz, 3H) ppm. ¹³C NMR (CDCl₃, 100 MHz): δ = 170.8 (C_q), 148.8 (C_q), 133.8 (CH), 129.0 (CH), 126.7 (C_q), 125.6 (CH), 122.1 (CH), 85.6 (C_q), 32.3 (2C, 2 × CH), 18.6 (CH₃), 15.6 (CH₃) ppm. IR (MIR-ATR, 4000–600 cm⁻¹): $\nu_{\rm max}$ = 2941, 1752, 1588, 1460, 1348, 1280, 1191, 1052, 966, 740, 690 cm⁻¹. HR-MS (ESI+) m/z calculated for [C₁₂H₁₄O₃Na]⁺ = [M + Na]⁺: 229.0835; found: 229.0830.

5,6-Dimethoxy-3-propylisobenzofuran-1(3H)-one (2bk). This compound was prepared according to the GP using petroleum ether/ethyl acetate (80:20) as eluent and isolated as a white colored solid 69% yield (82 mg): mp 82–84 °C; [TLC (petroleum ether/ethyl acetate 7:3, $R_{\rm f}({\rm 1bk})=0.40$, $R_{\rm f}({\rm 2bk})=0.30$, UV detection]. ¹H NMR (CDCl₃ 400 MHz): δ = 7.26 (s, 1H), 6.80 (s, 1H), 5.30–5.43 (m, 1H), 3.96 (s, 3H), 3.91 (s, 3H), 1.90–2.07 (m, 1H), 1.60–1.76 (m, 1H), 1.40–1.58 (m, 2H), 0.96 (t, J=7.3 Hz, 3H) ppm. ¹³C NMR (CDCl₃, 100 MHz): δ = 171.0 (C_q), 154.7 (C_q), 150.3 (C_q), 144.7 (C_q), 118.0 (C_q), 106.1 (CH), 103.0 (CH), 80.6 (C_q), 56.4 (CH₃), 56.3 (CH₃), 36.9 (CH₂), 18.2 (CH₂), 13.8 (CH₃) ppm. IR (MIR-ATR, 4000–600 cm⁻¹): $\nu_{\rm max}=2939$, 1749, 1582, 1463, 1345, 1286, 1181, 1050, 962, 758, 689 cm⁻¹. HR-MS (ESI+) m/z calculated for [C₁₃H₁₇O₄]⁺ = [M + H]⁺: 237.1121; found: 237.1115.

5,6,7-Trimethoxy-3-propylisobenzofuran-1(3H)-one (*2bl*). This compound was prepared according to the GP using petroleum ether/ethyl acetate (75:25) as eluent and isolated as a colorless oil 67% yield (89 mg): [TLC (petroleum ether/ethyl acetate 6:4, $R_{\rm f}({\bf 1bl}) = 0.50$, $R_{\rm f}({\bf 2bl}) = 0.40$, UV detection]. ¹H NMR (CDCl₃ 400 MHz): δ = 6.56 (s, 1H), 5.20–5.30 (m, 1H), 4.11 (s, 3H), 3.93 (s, 3H), 3.84 (s, 3H), 1.88–2.00 (m 1H), 1.60–1.75 (m 1H), 1.40–1.55 (m 2H), 0.95 (t, J = 7.3 Hz, 3H) ppm. ¹³C NMR (CDCl₃, 100 MHz): δ = 168.2 (C_q), 159.5 (C_q), 152.3 (C_q), 148.0 (C_q), 141.6 (C_q), 110.6 (C_q), 99.1 (CH), 79.8 (CH), 62.3 (CH₃), 61.4 (CH₃), 56.4 (CH₃), 37.0 (CH₂), 18.2 (CH₂), 13.8 (CH₃) ppm. IR (MIR-ATR, 4000–600 cm⁻¹): $\nu_{\rm max} = 2943$, 1742, 1578, 1462, 1341, 1282, 1187, 1054, 960, 757, 687 cm⁻¹. HR-MS (ESI+) m/z calculated for $[C_{14}H_{18}O_{5}Na]^{+} = [M + Na]^{+}$: 289.1046; found: 289.1038.

3-Cyclohexyl-5-methoxyisobenzofuran-1(3H)-one (2bn). This compound was prepared according to the GP using petroleum ether/ethyl acetate (85:15) as eluent and isolated as a white colored solid 66% yield (81 mg): mp 200–202 °C; [TLC (petroleum ether/ethyl acetate 8:2, R_f (1bn) = 0.50, R_f (2bn) = 0.40, UV detection]. ¹H NMR (CDCl₃ 400 MHz): δ = 7.76 (d, J = 8.3 Hz, 1H), 6.99 (dd, J = 2.0 and 8.3 Hz, 1H), 6.84 (d, J = 2.0 Hz, 1H), 5.24 (d, J = 3.4 Hz, 1H), 3.89 (s, 3H), 1.55–1.95 (m, 5H), 1.00–1.40 (m, 6H) ppm. ¹³C NMR (CDCl₃, 100 MHz): δ = 170.6 (C_q), 164.5 (C_q), 151.5 (C_q), 127.1 (CH), 119.0 (C_q), 115.9 (CH), 106.4 (CH), 84.6 (CH), 55.8 (CH₃), 42.0 (CH), 29.3 (CH₂), 26.2 (CH₂), 26.0 (CH₂), 25.8 (CH₂), 25.6 (CH₂) ppm. IR (MIR-ATR, 4000–600 cm⁻¹): ν_{max} = 2940, 1739, 1568, 1469, 1340, 1282, 1187, 1054, 964, 752, 686 cm⁻¹. HR-MS (ESI +) m/z calculated for [C₁₅H₁₈O₃K]⁺ = [M + K]⁺: 285.0888; found: 285.0882.

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.joc.6b01396.

Copies of NMR spectra (PDF) CIF data for **2bq** (CIF) CIF data for **2br** (CIF)

AUTHOR INFORMATION

Corresponding Author

*E-mail: gvsatya@iith.ac.in. Fax: +91(40) 2301 6032.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

We are grateful to the Department of Science and Technology-Science and Engineering Research Board (DST-SERB) [no. SB/S1/OC-39/2014], New Delhi, for financial support. L.M. thanks CSIR, New Delhi, for the award of a research fellowship.

REFERENCES

(1) (a) Karmakar, R.; Pahari, P.; Mal, D. Chem. Rev. 2014, 114, 6213. (b) Lin, G.; Chan, S. S.-K.; Chung, H.-S.; Li, S.-L. Chemistry and Biological Action of Natural Occurring Phthalides. In Studies in Natural Products Chemistry; Atta-ur-Rahman, Ed.; Elsevier: Amsterdam, 2005; Vol. 32, pp 611. (c) Xioang, M.-J.; Li, Z.-H. Curr. Org. Chem. 2007, 11, 833. (d) Di Mola, A.; Palombi, L.; Massa, A. Curr. Org. Chem. 2012, 16, 2302. (e) Beck, J. J.; Chou, S.-C. J. Nat. Prod. 2007, 70, 891.

(2) (a) Donner, C. D. Tetrahedron 2013, 69, 3747. (b) Mal, D.; Pahari, P. Chem. Rev. 2007, 107, 1892. (c) Snieckus, V. Chem. Rev. 1990, 90, 879. (d) Mitchell, A. S.; Russell, R. A. Tetrahedron 1995, 51, 5207. (e) Hernández, E.; Vélez, J. M.; Vlaar, C. P. Tetrahedron Lett. 2007, 48, 8972. (f) Rathwell, K.; Brimble, M. A. Synthesis 2007, 2007, 643.

- (3) (a) Larock, R. C.; Fellows, C. A. J. Am. Chem. Soc. 1982, 104, 1900. (b) Larock, R. C. Heterocycles 1982, 18, 397. (c) Franck, R. W.; John, T. V. J. Org. Chem. 1980, 45, 1170. (d) Snieckus, V. A. Heterocycles 1980, 14, 1649. (e) Hauser, F. M.; Rhee, R. P.; Prasanna, S.; Weinreb, S. M.; Dodd, J. H. Synthesis 1980, 1980, 72. (f) Larock, R. C.; Fellows, C. A. J. Org. Chem. 1980, 45, 363.
- (4) (a) Cowell, A.; Stille, J. K. J. Am. Chem. Soc. 1980, 102, 4193. (b) Kadnikov, D. V.; Larock, R. C. J. Org. Chem. 2003, 68, 9423. (c) Ito, M.; Osaku, A.; Shiibashi, A.; Ikariya, T. Org. Lett. 2007, 9, 1821. (d) Wu, H.-J.; Ying, F.-H.; Shao, W.-D. J. Org. Chem. 1995, 60, 6168. (e) Eildal, J. N. N.; Andersen, J.; Kristensen, A. S.; Jørgensen, A. M.; Bang-Andersen, B.; Jørgensen, M.; Strømgaard, K. J. Med. Chem. 2008, 51, 3045. (f) Kondo, Y.; Asai, M.; Miura, T.; Uchiyama, M.; Sakamoto, T. Org. Lett. 2001, 3, 13. (g) Murray, A. W.; Murray, N. D.; Reid, R. G. J. Chem. Soc., Chem. Commun. 1986, 1230. (h) Kushner, S.; Morton, J.; Boothe, J. H.; Williams, J. H. J. Am. Chem. Soc. 1953, 75, 1097. (i) Mahendar, L.; Satyanarayana, G. J. Org. Chem. 2015, 80, 7089.
- (5) (a) Prasad, P. K.; Sudalai, A. Adv. Synth. Catal. 2014, 356, 2231.
 (b) Chang, H.-T.; Jeganmohan, M.; Cheng, C.-H. Chem. Eur. J. 2007, 13, 4356.
 (c) Karthikeyan, J.; Parthasarathy, K.; Cheng, C.-H. Chem. Commun. 2011, 47, 10461.
 (d) Li, W.; Wu, X.-F. Adv. Synth. Catal. 2015, 357, 3393.
- (6) For reviews on domino reactions, see: (a) Tietze, L. F. Chem. Rev. 1996, 96, 115. (b) Shiri, M. Chem. Rev. 2012, 112, 3508. (c) Pellissier, H. Chem. Rev. 2013, 113, 442. (d) Zeng, X. Chem. Rev. 2013, 113, 6864.
- (7) (a) Gulevich, A. V.; Dudnik, A. S.; Chernyak, N.; Gevorgyan, V. Chem. Rev. 2013, 113, 3084. (b) Dandia, A.; Joshi, J.; Kumari, S.; Gupta, S. L. Chem. Biol. Interface 2013, 3, 61. (c) Wang, Y.; Liao, Q.; Xi, C. Org. Lett. 2010, 12, 2951. (d) Hartwig, J. F. Organotransition Metal Chemistry: From Bonding to Catalysis; University Science Books: Sausalito, CA, 2010 and Beller, M.; Bolm, C. Transition Metals for Organic Synthesis, 2nd ed.; University Science Books: Sausalito, CA, 2004.
- (8) (a) Mahendar, L.; Krishna, J.; Reddy, A. G. K.; Ramulu, B. V.; Satyanarayana, G. Org. Lett. 2012, 14, 628. (b) Mahendar, L.; Satyanarayana, G. J. Org. Chem. 2014, 79, 2059. (c) Krishna, J.; Reddy, A. G. K.; Satyanarayana, G. Synlett 2013, 24, 967. (d) Krishna, J.; Reddy, A. G. K.; Satyanarayana, G. Tetrahedron Lett. 2014, 55, 861. (e) Mahendar, L.; Reddy, A. G. K.; Krishna, J.; Satyanarayana, G. J. Org. Chem. 2014, 79, 8566. (f) Ravi Kumar, D.; Satyanarayana, G. Org. Lett. 2015, 17, 5894.
- (9) (a) Wu, X.-F.; Schranck, J.; Neumann, H.; Beller, M. Chem. Eur. J. 2011, 17, 12246. (b) Wu, X.-F.; Neumann, H.; Beller, M. Chem. Eur. J. 2012, 18, 12599.
- (10) (a) Wu, L.; Liu, Q.; Jackstell, R.; Beller, M. Angew. Chem., Int. Ed. 2014, 53, 6310. (b) Morimoto, T.; Kakiuchi, K. Angew. Chem., Int. Ed. 2004, 43, 5580.
- (11) (a) Friis, S. D.; Taaning, R. H.; Lindhardt, A. T.; Skrydstrup, T. J. Am. Chem. Soc. 2011, 133, 18114. (b) Hermange, P.; Gøgsig, T. M.; Lindhardt, A. T.; Taaning, R. H.; Skrydstrup, T. Org. Lett. 2011, 13, 2444. (c) Nielsen, D. U.; Neumann, K.; Taaning, R. H.; Lindhardt, A. T.; Modvig, A.; Skrydstrup, T. J. Org. Chem. 2012, 77, 6155. (d) Gøgsig, T. M.; Nielsen, D. U.; Lindhardt, A. T.; Skrydstrup, T. Org. Lett. 2012, 14, 2536. (e) Burhardt, M. N.; Taaning, R. H.; Skrydstrup, T. Org. Lett. 2013, 15, 948. (f) Brancour, C.; Fukuyama, T.; Mukai, Y.; Skrydstrup, T.; Ryu, I. Org. Lett. 2013, 15, 2794. (g) Korsager, S.; Taaning, R. H.; Lindhardt, A. T.; Skrydstrup, T. J. Org. Chem. 2013, 78, 6112.
- (12) (a) Li, H.; Neumann, H.; Beller, M.; Wu, X.-F. Angew. Chem., Int. Ed. 2014, 53, 3183. (b) Wu, X.-F.; Sharif, M.; Shoaib, K.; Neumann, H.; Pews-Davtyan, A.; Langer, P.; Beller, M. Chem. Eur. J. 2013, 19, 6230.
- (13) (a) Natte, K.; Dumrath, A.; Neumann, H.; Beller, M. Angew. Chem., Int. Ed. **2014**, 53, 10090. (b) Li, W.; Wu, X.-F. J. Org. Chem. **2014**, 79, 10410.

- (14) (a) Fuji, K.; Morimoto, T.; Tsutsumi, K.; Kakiuchi, K. Chem. Commun. 2005, 3295. (b) Morimoto, T.; Fujioka, M.; Fuji, K.; Tsutsumi, K.; Kakiuchi, K. J. Organomet. Chem. 2007, 692, 625.
- (15) Markovič, M.; Lopatka, P.; Koóš, P.; Gracza, T. Org. Lett. 2015, 17, 5618.
- (16) (a) Mitsuhashi, H.; Muramatsu, T.; Nagai, U.; Nakano, T.; Ueno, K. Chem. Pharm. Bull. 1963, 11, 1317. (b) Diao, X.; Deng, P.; Xie, C.; Li, X.; Zhong, D.; Zhang, Y.; Chen, X. Drug Metab. Dispos. 2013, 41, 430. (c) Wang, W.; Cha, X.-X.; Reiner, J.; Gao, Y.; Qiao, H.-L.; Shen, J.-X.; Chang, J.-B. Eur. J. Med. Chem. 2010, 45, 1941. (d) Chapuis, A.; Paolo, R. G.; D'Agostino, C.; Attinger, A.; Knabenhans, C.; Fleury, S.; Acha-Orbea, H.; Pantaleo, G. Nat. Med. 2000, 6, 762. (e) Floryk, D.; Huberman, E. Cancer Lett. 2006, 231, 20. (f) Rana, N. M.; Sargent, M. V.; Elix, J. A. J. Chem. Soc., Perkin Trans. 1 1975, 1992.
- (17) Komala, I.; Ito, T.; Nagashima, F.; Yagi, Y.; Asakawa, Y. Nat. Prod. Commun. 2011, 6, 303.